U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07743580) titled 'A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease' on July 30.

Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.

Study Start Date: Aug. 06

Study Type: INTERVENTIONAL

Condition: SARS-CoV-2

Intervention: DRUG: Secutrelvir

Secutrelvir will be administered orally as a tablet.

DRUG: Placebo

Placebo will be administered orally as a tablet.

Recruitment Status: NO...